Literature DB >> 28204987

The effects of topical carbonic anhydrase inhibitor in treatment of nystagmus.

Ebru Demet Aygit1, Osman Bulut Ocak2, Aslı İnal2, Korhan Fazıl2, Serpil Akar2, Birsen Gokyigit2.   

Abstract

OBJECTIVE: To evaluate the effects of topical carbonic anhydrase inhibitor (CAI), brinzolamide (Azopt), for treatment of nystagmus patients.
MATERIALS AND METHODS: Patients who used Brinzolamide for treatment of nystagmus were retrospectively analyzed. 23 patients were included in this study. The patients' diagnosis were idiopathic infantile nystagmus 18 (78.2%) and oculocutaneous albinism in 5 (21.8%). Azopt eye drop was used in both eyes, 3 times a day. Detailed eye examination in all of the patients before treatment and repeated at the end of the first week after treatment. SPSS 16.0 computer program was used for evaluation of DATAs.
RESULTS: The mean follow-up was 32 ± 28 months. 23 patients 15 (65.2%) were male and 8 (34.7%) were female and the mean age was 12.6 ± 5.5. Before the management of topical brinzolamide, abnormal head position (AHP) were observed in 18 patients. After that we found reduction of nystagmus in 5 (22.7%) of the patients, increase in vision in 9 (40.9%) and reduced AHP in 18.3%. There is no identified change in 4 (18.1%).
CONCLUSION: The medical treatment of nystagmus with topical brinzolamide was found effective in our series but, wider series and longer follow-up studies are needed.

Entities:  

Keywords:  Carbonic anhydrase inhibitor; Infantile Nystagmus Syndrome; Nystagmus; Oculocutaneos albinism

Mesh:

Substances:

Year:  2017        PMID: 28204987     DOI: 10.1007/s10792-017-0456-z

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  25 in total

1.  Horizontal rectus muscle tenotomy in children with infantile nystagmus syndrome: a pilot study.

Authors:  Richard W Hertle; Louis F Dell'Osso; Edmond J FitzGibbon; Dongsheng Yang; Susan D Mellow
Journal:  J AAPOS       Date:  2004-12       Impact factor: 1.220

2.  The application of hard contact lenses in patients with congenital nystagmus.

Authors:  S Golubović; S Marjanović; D Cvetković; S Manić
Journal:  Fortschr Ophthalmol       Date:  1989

3.  Effects of topical brinzolamide on infantile nystagmus syndrome waveforms: eyedrops for nystagmus.

Authors:  Louis F Dell'osso; Richard W Hertle; R John Leigh; Jonathan B Jacobs; Susan King; Stacia Yaniglos
Journal:  J Neuroophthalmol       Date:  2011-09       Impact factor: 3.042

4.  Prevalence and inheritance of congenital nystagmus in a Swedish population.

Authors:  B Forssman; B Ringnér
Journal:  Ann Hum Genet       Date:  1971-10       Impact factor: 1.670

5.  The effect of habituating vestibular and optokinetic nystagmus on each other.

Authors:  A A Skavenski; S M Blair; G Westheimer
Journal:  J Neurosci       Date:  1981-04       Impact factor: 6.167

6.  Topical brinzolamide (Azopt) versus placebo in the treatment of infantile nystagmus syndrome (INS).

Authors:  Richard W Hertle; Dongsheng Yang; Tonia Adkinson; Michael Reed
Journal:  Br J Ophthalmol       Date:  2014-10-21       Impact factor: 4.638

7.  Motor and sensory characteristics of infantile nystagmus.

Authors:  R V Abadi; A Bjerre
Journal:  Br J Ophthalmol       Date:  2002-10       Impact factor: 4.638

Review 8.  A unifying neurologic mechanism for infantile nystagmus.

Authors:  Michael C Brodsky; Louis F Dell'Osso
Journal:  JAMA Ophthalmol       Date:  2014-06       Impact factor: 7.389

9.  The prevalence of nystagmus: the Leicestershire nystagmus survey.

Authors:  Nagini Sarvananthan; Mylvaganam Surendran; Eryl O Roberts; Sunila Jain; Shery Thomas; Nitant Shah; Frank A Proudlock; John R Thompson; Rebecca J McLean; Christopher Degg; Geoffrey Woodruff; Irene Gottlob
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-05-20       Impact factor: 4.799

10.  Partial sight and blindness in children of the 1970 birth cohort at 10 years of age.

Authors:  S L Stewart-Brown; M N Haslum
Journal:  J Epidemiol Community Health       Date:  1988-03       Impact factor: 3.710

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.